Literature DB >> 2843102

Purification and characterization of a collagenase inhibitor produced by bovine vascular smooth muscle cells.

Y A DeClerck1.   

Abstract

A potent polypeptide inhibitor of mammalian collagenases was purified to homogeneity from medium conditioned by bovine aortic smooth muscle cells maintained in culture. This inhibitor was purified by a series of molecular sieve and heparin-Sepharose chromatographic procedures; it had an apparent Mr of 28,500 and was a major protein secreted by the smooth muscle cells. It was found to be active against several mammalian collagenases including those obtained from rabbit and human fibroblasts and a tumor-specific type IV collagenase. In contrast, it had minimal inhibitory activity for bacterial collagenase and was inactive against the serine proteases plasmin and trypsin. The inhibitor shared many characteristics with tissue inhibitor of metalloproteinases including the ability to irreversibly inhibit susceptible proteinases, heat and acid resistance, and sensitivity to trypsin degradation and reduction-alkylation. A polyclonal rabbit antiserum with blocking activity which recognized the Mr 28,500 protein was obtained. This inhibitor, which is likely produced by bovine vascular smooth muscle cells in vivo to protect the collagen matrix of blood vessels, may play an important role in pathological conditions associated with alteration of collagen metabolism in tissues.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843102     DOI: 10.1016/0003-9861(88)90367-0

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  9 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Hormonal regulation of collagenolysis in uterine cervical fibroblasts. Modulation of synthesis of procollagenase, prostromelysin and tissue inhibitor of metalloproteinases (TIMP) by progesterone and oestradiol-17 beta.

Authors:  T Sato; A Ito; Y Mori; K Yamashita; T Hayakawa; H Nagase
Journal:  Biochem J       Date:  1991-05-01       Impact factor: 3.857

Review 3.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

4.  Identification, purification and partial characterization of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in bovine pulmonary artery smooth muscle.

Authors:  Malay Mandal; Sudip Das; Tapati Chakraborti; Amritlal Mandal; Sajal Chakraborti
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

5.  Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization.

Authors:  S M Nordstrom; S M Carleton; W L Carson; M Eren; C L Phillips; D E Vaughan
Journal:  Bone       Date:  2007-08-17       Impact factor: 4.398

6.  beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.

Authors:  B A Teicher; E A Sotomayor; Z D Huang; G Ara; S Holden; V Khandekar; Y N Chen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Characterization of the functional domain of tissue inhibitor of metalloproteinases-2 (TIMP-2).

Authors:  Y A DeClerck; T D Yean; Y Lee; J M Tomich; K E Langley
Journal:  Biochem J       Date:  1993-01-01       Impact factor: 3.857

8.  Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.

Authors:  E A Sotomayor; B A Teicher; G N Schwartz; S A Holden; K Menon; T S Herman; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases.

Authors:  Z S Zeng; J G Guillem
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.